CMS May Clarify Drugs’ “Negotiated Price” To Address Cost Shifting In Part D
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS acknowledges its current definition of negotiated prices for drugs could be interpreted as permitting Medicare Part D plans to overstate them, which may move beneficiaries more quickly to the coverage gap and beyond, when beneficiaries, the government and drug firms incur greater responsibility for costs.